To allow such combinations, MS~IL-15 agonists would be deposited into the tumor along with concurrent systemic treatment with the second drug; the tumor would be exposed to both agents whereas other tissues are exposed only to the systemically administered agent (56). This evidence concerns the gene IL15 and neoplasm.